Repros Therapeutics' cash falls 41%, research and development costs rise 87%

By Lisa Kerner

Charlotte, N.C., Nov. 13 - Repros Therapeutics Inc. ended the third quarter with cash, cash equivalents and marketable securities of $9.9 million at Sept. 30, compared with $16.8 million at Dec. 31, 2005.

The company reported a net loss of $3.6 million, or $0.36 per share, for the third quarter, compared with a net loss of $1.9 million, or $0.19 per share, for the quarter ended Sept. 30, 2005.

Total revenues, primarily consisting of interest income, for the third quarter were $146,000, down from $175,000 for the same period of 2005.

Research and development expenses rose 87% for the quarter to $3.1 million, from $1.6 million for the third quarter of 2005.

General and administrative expenses for the three-month period increased 55% to $713,000, from $461,000 for the prior-year period.

The net loss for the first nine months of 2006 was $8.7 million, or $0.86 per share, versus a net loss of $5.1 million, or $0.54 per share, for the year-ago period.

For the nine months ended Sept. 30, the company's total revenues rose slightly to $486,000, from $460,000 for the same period of 2005.

Research and development expenses increased 71% to $7.2 million and general and administrative expenses increased 47% to $2.0 million for the nine-month period compared with the first nine months of 2005.

Repros is a pharmaceutical products company based in The Woodlands, Texas.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.